Beyond Air, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $4.6M
- Price
- $6.32
- % Change (Daily % change from the live per-ticker quote feed.)
- -8.74%
- Volume
- 15.3K
About
Beyond Air, Inc. functions as a specialized entity involved in both the development of medical devices and biopharmaceutical solutions. A central part of its operations is the LungFit platform, an innovative system that generates and delivers nitric oxide. Within this platform, LungFit PH is currently available, used to address persistent pulmonary hypertension in infants. Furthermore, the company is advancing LungFit PRO, a product intended for various viral lung ailments like community-acquired viral pneumonia (including COVID-19) and bronchiolitis in hospital settings. It is also creating LungFit GO, which aims to treat nontuberculous mycobacteria infections. The organization adopted its current name, Beyond Air, Inc., in June 2019, having previously been known as AIT Therapeutics, Inc. Its headquarters are situated in Garden City, New York.
Quick stats
Shares outstanding720.5K
Computed float530.6K
Float / shares73.6%
Cash runway (months)3.1
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001641631
Websitehttps://www.beyondair.net
AI Summary
AI-generated1/13
standardbullishearnings
Beyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update
Beyond Air reported Q2 revenue of $1.8 million, flat compared to the prior year, while gross margins improved to 13%.
The company secured up to $30.1 million in financing to support its commercial launch, consisting of $10.2 million in upfront proceeds and additional warrant exercises.
Management reaffirmed full-year 2026 guidance of $8 million and 2027 guidance of $16-$18 million, backed by a new group purchasing agreement covering nearly 2,000 U.S. hospitals.
Red flags
- 1-for-20 reverse stock split completed in July 2026
- Financing includes up to $20 million in warrant exercises contingent on FDA approval